… These experiments served as a basis for the development of anti-cytokine therapeutic
strategies in sepsis, such as inhibitors of TNFα, IL1β and platelet-activating factor. Several large…

… Thus much more needs to be understood about sepsis and processes underpinning its
development if we are either to optimize these present clinical therapies or develop novel …

… trials of immune-adjuvant therapies in sepsis must be based on … sepsis or septic shock were
treated with GM-CSF or placebo. Inclusions were restricted to patients presenting with sepsis…

… sepsis. Here we focus on studies developing TLR agonists and antagonists for the treatment
of infectious diseases and sepsis. … targets for developing anti-sepsis drugs, and antagonistic …

… with sepsis and septic shock. This article reviews principles in the rational use of antibiotics
in sepsis and presents evidence-based recommendations for optimal antibiotic therapy. …

… for the rapid identification of infections, rational employment of antibiotics, evaluation of the
affection of interventions, therapeutic monitoring of organ function for prognosis, and so on. …

… sepsis redox cycle represent the main cause of dysfunction of mitochondria and cells in
neonatal sepsis. Our aim here is to support the new philosophy in neonatal sepsis treatment, …

… with sepsis and septic shock. This article reviews sepsis pathophysiology and the rational use
of … to hold an important place in the therapeutic armamentarium of sepsis and septic shock …

… evolution of sepsis therapy (Table 1) and identifies possible causes for why rational therapies
failed in human trials. In addition, this article examines potential future sepsis targets and …

… septic shock, a rational approach may be to incorporate combination therapy in the opening
salvo of treatment … In theory, combination therapy would only be required while the microbial …